Intravenous amiodarone and subsequent guideline-directed medical therapy led to normalization of LVEF from 22% to 56% at three months in a patient with reversible tachycardia-induced cardiomyopathy.
Case Report (n=1)
No
A 51-year-old previously healthy woman presenting with palpitations, chest pain, and hemodynamically stable wide complex tachycardia (QRS 114 ms, 192 bpm) with reduced LVEF (22%) due to tachycardia-induced cardiomyopathy.
Intravenous amiodarone bolus followed by guideline-directed medical therapy (sacubitril-valsartan, spironolactone, dapagliflozin, and a beta-blocker).
Hemodynamically stable wide complex tachycardia should be carefully evaluated to distinguish SVT with aberrancy from VT, and tachycardia-induced cardiomyopathy can be fully reversible with appropriate management.
Absolute Event Rate: 56% vs 22%
Wide complex tachycardia (WCT) is often treated as ventricular tachycardia (VT). However, it can also be supraventricular tachycardia (SVT) with aberrant conduction, which is rarely life-threatening. Accurately differentiating VT from SVT with aberrancy guides appropriate therapy. We present a case that highlights the value of structured electrocardiogram (ECG) analysis in hemodynamically stable WCT and demonstrates reversible alcohol-related SVT-induced cardiomyopathy in a patient with familial susceptibility. A 51-year-old previously healthy woman presented to urgent care with four hours of palpitations and sharp substernal chest pain radiating to the right neck, accompanied by anxiety, nausea, and mild dyspnea. She had consumed alcohol heavily two days earlier and was hemodynamically stable. ECG showed a regular borderline WCT (QRS 114 milliseconds) at 192 beats per minute, flagged by machine interpretation as possible acute MI, prompting urgent transfer to the emergency department (ED). En route, she received IV amiodarone with resolution of symptoms. In the ED, repeat ECG revealed sinus WCT (QRS 121 milliseconds, at 105 beats per minute) with a left bundle branch block. Troponins and electrolytes were normal. Echocardiogram demonstrated a left ventricular ejection fraction (LVEF) of 22%. Invasive coronary angiography showed no obstructive disease. Cardiac MRI revealed no late gadolinium enhancement. She was started on full guideline-directed medical therapy (GDMT). Further history revealed prior vagal-responsive palpitations and a child with SVT requiring ablation. She was discharged with a 14-day ambulatory monitor showing SVT burden <0.01%. At the three-month follow-up, her LVEF had normalized to 56%. Carvedilol was discontinued due to bradycardia, while other GDMT was continued. This case highlights the value of structured ECG analysis in hemodynamically stable WCT, where careful review, using tools like the Brugada criteria, can distinguish SVT with aberrancy from VT and avoid inappropriate exposure to amiodarone. Although empiric treatment for presumed VT is reasonable when uncertainty exists, clinical stability often allows time for systematic ECG assessment to prevent overtreatment. The patient’s complete recovery demonstrates the reversibility of TIC and reinforces the importance of continuing GDMT even after LVEF normalization to reduce relapse risk.
Building similarity graph...
Analyzing shared references across papers
Loading...
Admire Hlupeni
Rabbia Haider
Jonas A. Cooper
Cureus
Building similarity graph...
Analyzing shared references across papers
Loading...
Hlupeni et al. (Sun,) conducted a case report in Middle-aged woman (51 years) with hemodynamically stable wide complex tachycardia and reversible tachycardia-induced cardiomyopathy with severe left ventricular dysfunction (LVEF 22%) (n=1). Intravenous amiodarone; guideline-directed medical therapy including sacubitril-valsartan, spironolactone, dapagliflozin, and beta-blocker (carvedilol) vs. None was evaluated on Normalization of left ventricular ejection fraction (LVEF) from severely reduced at 22% to normal at 56%. Intravenous amiodarone and subsequent guideline-directed medical therapy led to normalization of LVEF from 22% to 56% at three months in a patient with reversible tachycardia-induced cardiomyopathy.
synapsesocial.com/papers/69a67ed1f353c071a6f0a641 — DOI: https://doi.org/10.7759/cureus.104485